Pharma and BioTech Daily: FDA Approves Alnylam's Amvuttra for Rare Cardiovascular Disease, Sparking Competition with Pfizer and BridgeBio

Release Date: March 24, 2025

Introduction

In the latest episode of Pharma and BioTech Daily, hosted by Pharma and BioTech News, listeners are presented with a comprehensive overview of the most pressing developments in the pharmaceutical and biotechnology sectors. The episode delves into regulatory approvals, corporate strategies, competitive dynamics, and significant financial movements shaping the industry landscape.

Regulatory Updates

FDA Approval of Alnylam's Amphitra

A cornerstone of the episode is the FDA's recent approval of Alnylam's Amphitra, marking it as the first RNA silencer for a rare type of cardiovascular disease known as ttrcm (transthyretin cardiac amyloidosis). This approval follows the earlier authorization of BridgeBio's Zatruzi for the same condition, igniting a competitive three-way race that now includes Pfizer's Tefamidis.

“The FDA has approved Alnylam's Amphitra as the first RNA silencer for a rare type of cardiovascular disease called a ttrcm, following the approval of Bridgebio Zatruzi for the same condition.” [00:00]

This milestone positions Alnylam at the forefront of innovative treatments targeting the disease's root cause by effectively reducing the disease-causing TTR protein. The approval also comes on the heels of Amphitra's success in treating polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in June 2022, further solidifying its therapeutic potential.

Other Notable Approvals

• J&J's Tremphya has secured approval for expanded use in treating Crohn's disease, broadening its market presence.
• Novartis' Fabhada gains approval as the first therapy for a rare kidney disease, addressing unmet medical needs in nephrology.
• Novartis' Zolgensma is recognized for its effectiveness in treating older children, expanding its application beyond initial pediatric populations.

Company Developments

Johnson & Johnson (J&J)

J&J announced plans to bolster its U.S. manufacturing capabilities in response to tariff-related challenges, underscoring its commitment to maintaining a robust domestic supply chain.

“J&J plans to boost U.S. manufacturing following tariff.” [00:00]

Additionally, J&J's Tremphya's expansion into Crohn's disease treatment signifies the company's strategic efforts to diversify its therapeutic portfolio.

Sanofi's Strategic Investment

Sanofi has committed up to $1.9 billion towards DrenBio's bispecific antibody program targeting autoimmune diseases. This substantial investment highlights Sanofi's dedication to advancing novel therapeutic modalities in immunology.

“Sanofi commits up to $1.9 billion for DrenBio's bispecific antibody for autoimmune diseases.” [00:00]

Paratech Acquires Optinos

In a significant corporate move, Paratech has acquired Optinos for up to $330 million, aiming to enhance its technological capabilities and expand its market footprint.

“Paratech has acquired Optinos for up to $330 million.” [00:00]

Competitive Dynamics

The approval of Alnylam's Amphitra sets the stage for intense competition with Pfizer and BridgeBio in the treatment of ttrcm. Each company's approach offers unique mechanisms of action:

• Alnylam's Amphitra focuses on silencing RNA to reduce TTR protein levels.
• BridgeBio's Zatruzi and Pfizer's Tefamidis offer alternative therapeutic strategies targeting the same disease pathway.

This competitive environment is expected to spur further innovations and potentially drive down treatment costs, benefiting patients with rare cardiovascular conditions.

“Alnilam is optimistic about Amvitra's unique mechanism of action, which targets the disease at its source by rapidly reducing the disease causing TTR protein.” [00:00]

Financial News

Adaptimmune's Financial Uncertainty

Despite generating sales from its T cell therapy products, Adaptimmune is currently facing financial uncertainty. This situation underscores the volatility inherent in the biotech sector, where promising therapies must navigate complex financial landscapes to achieve sustainable growth.

“Adaptimmune is facing financial uncertainty despite sales of its T cell therapy.” [00:00]

Purdue Pharma's Bankruptcy Filing

In legal developments, Purdue Pharma has filed for bankruptcy amid ongoing negotiations surrounding its opioid settlement. This move is a significant event in the pharmaceutical industry's response to the opioid crisis, with far-reaching implications for stakeholders.

“Purdue Pharma has filed for bankruptcy opioid settlement.” [00:00]

Research and Development

Sinobiological's Influenza Vaccine Reagents

Sinobiological has made strides in developing reagents tailored for the 2025-2026 influenza vaccine strains. This advancement is crucial for enhancing vaccine efficacy and preparedness for upcoming influenza seasons.

“Sinobiological has developed reagents for the 20252026 influenza vaccine strains.” [00:00]

Novartis' Zolgensma in Pediatric Use

Novartis' Zolgensma, initially approved for younger children, has been found effective in older pediatric populations. This extension broadens the drug's applicability, offering therapeutic benefits to a wider age range of patients suffering from genetic disorders.

“Novartis Zolgensma has been found effective in older children.” [00:00]

Market Insights and Trends

The approval of Amphitra and the ensuing competition among major pharmaceutical companies highlight a broader trend of renewed focus on cardiovascular diseases, particularly those that are rare and genetically mediated. This trend reflects an increasing recognition of the need for targeted therapies that address specific molecular pathways, offering personalized treatment options for patients.

Moreover, significant investments in antibody therapies and RNA silencing technologies indicate a shift towards more sophisticated and precise therapeutic modalities. Companies are leveraging advancements in biotechnology to develop drugs that not only treat symptoms but also modify disease progression at the genetic and molecular levels.

Conclusion

This episode of Pharma and BioTech Daily underscores the dynamic and multifaceted nature of the pharmaceutical and biotechnology industries. From groundbreaking FDA approvals and strategic corporate acquisitions to financial uncertainties and innovative research, the sector continues to evolve rapidly. The competitive race triggered by Alnylam's Amphitra approval exemplifies the relentless pursuit of innovation aimed at improving patient outcomes in rare and complex diseases. As the industry navigates these developments, stakeholders remain attentive to the intersecting forces of regulation, competition, and scientific advancement shaping the future of healthcare.

For more detailed daily updates in the pharma and biotech world, visit our website at Pharma and BioTech Daily.